The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway

PLoS Medicine

Volumn 6, Issue 10, 2009, Pages

  Gordon, Ira ^a   Paoloni, Melissa ^a   Mazcko, Christina ^a   Khanna, Chand ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; PROTEIN;

CANCER MODEL; CANCER RESEARCH; CLINICAL PATHWAY; COST BENEFIT ANALYSIS; DOG; DRUG COST; DRUG RESEARCH; HUMAN; INTEGRATIVE MEDICINE; NONHUMAN; OUTCOME ASSESSMENT; PLANNING; REVIEW; SPECIES DIFFERENCE; ANIMAL; ANIMAL DISEASE; ANIMAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; DOG DISEASE; DOMESTIC ANIMAL; DRUG SCREENING; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; ORGANIZATION AND MANAGEMENT; PHASE 1 CLINICAL TRIAL; UNITED STATES;

ANIMALS; ANIMALS, DOMESTIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DOG DISEASES; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, ANIMAL; MULTICENTER STUDIES AS TOPIC; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; SPECIES SPECIFICITY; UNITED STATES;

EID: 70449091904     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000161     Document Type: Review

References (30)

1. Simon R (2008) Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 44: 2707-2713.
2. DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25: 209-216. (Pubitemid 350003036)
3. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
4. Roberts TG Jr, Lynch TJ Jr, Chabner BA (2003) The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol 21: 3683-3695.
5. Adams CP, Brantner VV (2006) Estimating the cost of new drug development: is it really $802 million? Health Aff 25: 420-428.
6. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, et al. (2008) Phase 0 clinical trials: conceptions and misconceptions. Cancer J 14: 133-137.
7. Porrello A, Cardelli P, Spugnini EP (2006) Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25: 97-105.
8. Porrello A, Cardelli P, Spugnini EP (2004) Pet models in cancer research: general principles. J Exp Clin Cancer Res 23: 181-193. (Pubitemid 38949834)
9. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156. (Pubitemid 351161319)
10. Pang LY, Argyle DJ (2009) Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta 1792: 308-391.
11. Pazzi KA, Kraegel SA, Griffey SM, Theon AP, Madewell BR (1996) Analysis of the equine tumor suppressor gene p53 in the normal horse and in eight cutaneous squamous cell carcinomas. Cancer Lett 107: 125-130.
12. Withrow SJ, Powers BE, Straw RC, Wilkins RM (1991) Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res. pp 159-168.
13. Madewell BR (1981) Neoplasms in domestic animals: a review of experimental and spontaneous carcinogenesis. Yale J Biol Med 54: 111-125.
14. Theilen GH, Hills D (1982) Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals. J Am Vet Med Assoc 181: 1134-1141.
15. Powers BE, McChesney SL, Gillette EL (1987) Late radiation response of the canine trachea with change in dose per fraction. Int J Radiat Oncol Biol Phys 13: 1673-1680.
16. Page RL, Thrall DE (1994) Therapeutic hyperthermia: contribution from clinical studies in dogs with spontaneous neoplasia. In Vivo 8: 851-858.
17. Mueller F, Fuchs B, Kaser-Hotz B (2007) Comparative biology of human and canine osteosarcoma. Anticancer Res 27: 155-164. (Pubitemid 46370589)
18. Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792.
19. Sulaimon SS, Kitchell BE (2003) The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 17: 760-772.
20. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, et al. (2003) Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9: 2755-2768. (Pubitemid 36842122)
21. Forrest LJ, Mackie TR, Ruchala K, Turek M, Kapatoes J, et al. (2004) The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. Int J Radiat Oncol Biol Phys 60: 1639-1644. (Pubitemid 39601882)
22. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, et al. (2008) Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv 21: 255-268.
23. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972. doi:10.1371/journal.pone.0004972.
24. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, et al. (1995) Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1: 1595-1601.
25. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, et al. (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26: 633-638.
26. Withrow SJ, Thrall DE, Straw RC, Powers BE, Wrigley RH, et al. (1993) Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71: 2484-2490.
27. Page RL, Thrall DE, Dewhirst MW, Meyer RE (1987) Whole-body hyperthermia. Rationale and potential use for cancer treatment. J Vet Intern Med 1: 110-120.
28. Dewhirst MW (1989) Animal modeling and thermal dose. Radiol Clin North Am 27: 509-518.
29. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, et al. (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 15: 3856-3865.
30. Breen M, Modiano JF (2008) Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res 16: 145-154. (Pubitemid 351294788)